Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focusing on rare diseases and multi-drug resistant (MDR) bacterial infections, has announced its upcoming second quarter 2024 financial results and business update. The company will host a conference call and live audio webcast on Monday, August 5th, 2024, at 4:30 p.m. ET.
Investors and interested parties can access the call by dialing 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and referring to conference ID 13747505. Alternatively, they can request a return call or access the live audio webcast through the provided link. The webcast will also be available on Spero's Investor Relations webpage and archived for 30 days following the call.
Spero Therapeutics (Nasdaq: SPRO), un'azienda biofarmaceutica in fase clinica focalizzata su malattie rare e infezioni batteriche multiresistenti (MDR), ha annunciato i risultati finanziari del secondo trimestre 2024 e un aggiornamento sulle attività. L'azienda ospiterà una conferenza telefonica e una trasmissione audio in diretta lunedì 5 agosto 2024, alle 16:30 ET.
Gli investitori e le parti interessate possono accedere alla chiamata componendo il numero 1-877-269-7751 (nazionale) o 1-201-389-0908 (internazionale) e facendo riferimento all'ID della conferenza 13747505. In alternativa, possono richiedere una chiamata di ritorno o accedere alla trasmissione audio in diretta tramite il link fornito. La trasmissione sarà inoltre disponibile sulla pagina web delle Relazioni con gli Investitori di Spero e archiviata per 30 giorni dopo la chiamata.
Spero Therapeutics (Nasdaq: SPRO), una compañía biofarmacéutica en etapa clínica que se centra en enfermedades raras e infecciones bacterianas multirresistentes (MDR), ha anunciado sus resultados financieros del segundo trimestre de 2024 y una actualización sobre el negocio. La compañía llevará a cabo una conferencia telefónica y una transmisión de audio en vivo el lunes 5 de agosto de 2024, a las 4:30 p.m. ET.
Los inversores y las partes interesadas pueden acceder a la llamada marcando el 1-877-269-7751 (nacional) o el 1-201-389-0908 (internacional) y refiriéndose a la ID de la conferencia 13747505. Alternativamente, pueden solicitar una devolución de llamada o acceder a la transmisión de audio en vivo a través del enlace proporcionado. La transmisión también estará disponible en la página de Relaciones con Inversores de Spero y se archivará durante 30 días después de la llamada.
Spero Therapeutics(Nasdaq: SPRO)는 희귀 질병 및 다제내성(MDR) 세균 감염에 초점을 맞춘 임상 단계 생물 의약품 회사로, 2024년 2분기 재무 실적 및 사업 업데이트를 발표하였습니다. 회사는 2024년 8월 5일 월요일 오후 4:30(ET)에 전화 회의 및 실시간 오디오 웹캐스트를 주최할 것입니다.
투자자 및 이해관계자는 1-877-269-7751(국내) 또는 1-201-389-0908(국제)로 전화하여 회의 ID 13747505를 참조하여 전화를 받을 수 있습니다. 또는, 제공된 링크를 통해 실시간 오디오 웹캐스트에 접속하거나 회신 전화를 요청할 수 있습니다. 웹캐스트는 Spero의 투자자 관계 웹페이지에서도 이용 가능하며, 통화 후 30일 동안 아카이브됩니다.
Spero Therapeutics (Nasdaq: SPRO), une entreprise biopharmaceutique en phase clinique axée sur les maladies rares et les infections bactériennes multirésistantes (MDR), a annoncé ses résultats financiers pour le deuxième trimestre de 2024 ainsi qu'une mise à jour sur ses activités. L'entreprise organisera une conférence téléphonique et une diffusion audio en direct le lundi 5 août 2024 à 16h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à l'appel en composant le 1-877-269-7751 (national) ou le 1-201-389-0908 (international) et en se référant à l'ID de la conférence 13747505. Alternativement, ils peuvent demander un rappel ou accéder à la diffusion audio en direct via le lien fourni. La diffusion sera également disponible sur la page des Relations avec les Investisseurs de Spero et archivée pendant 30 jours après l'appel.
Spero Therapeutics (Nasdaq: SPRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten und multiresistente (MDR) bakterielle Infektionen konzentriert, hat seine kommenden finanziellen Ergebnisse und Geschäftsaktualisierungen für das zweite Quartal 2024 angekündigt. Das Unternehmen wird am Montag, den 5. August 2024, um 16:30 Uhr ET eine Telefonkonferenz und einen Live-Audio-Webcast veranstalten.
Investoren und Interessierte können die Konferenz über die Telefonnummer 1-877-269-7751 (national) oder 1-201-389-0908 (international) erreichen und sich auf die Konferenz-ID 13747505 beziehen. Alternativ können sie eine Rückrufanfrage stellen oder über den bereitgestellten Link auf den Live-Audio-Webcast zugreifen. Der Webcast wird auch auf der Investor-Relations-Webseite von Spero verfügbar sein und 30 Tage nach der Konferenz archiviert werden.
- None.
- None.
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline.
To access the call, please dial 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and refer to conference ID 13747505, or click on this link and request a return call. The audio webcast can be accessed live on this link and also on the “Investor Relations” page of the Spero Corporate Website at https://sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information - www.sperotherapeutics.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
FAQ
When will Spero Therapeutics (SPRO) report its Q2 2024 financial results?
How can investors access Spero Therapeutics' (SPRO) Q2 2024 earnings call?
What is the focus of Spero Therapeutics (SPRO)?
Will Spero Therapeutics (SPRO) provide a business update during the Q2 2024 earnings call?
